- Home
- AMIX vs XRTX Comparison
AMIX vs XRTX Comparison
Compare AMIX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- XRTX
- Stock Information
- Founded
- AMIX 2014
- XRTX 2011
- Country
- AMIX United States
- XRTX Canada
- Employees
- AMIX N/A
- XRTX N/A
- Industry
- AMIX
- XRTX Pharmaceuticals and Biotechnology
- Sector
- AMIX
- XRTX Health Care
- Exchange
- AMIX NYSE
- XRTX Nasdaq
- Market Cap
- AMIX 3.5M
- XRTX 3.4M
- IPO Year
- AMIX N/A
- XRTX N/A
- Fundamental
- Price
- AMIX $1.58
- XRTX $0.96
- Analyst Decision
- AMIX Strong Buy
- XRTX
- Analyst Count
- AMIX 1
- XRTX 0
- Target Price
- AMIX $5.00
- XRTX N/A
- AVG Volume (30 Days)
- AMIX 2.4M
- XRTX 231.8K
- Earning Date
- AMIX 08-12-2025
- XRTX 08-13-2025
- Dividend Yield
- AMIX N/A
- XRTX N/A
- EPS Growth
- AMIX N/A
- XRTX N/A
- EPS
- AMIX N/A
- XRTX N/A
- Revenue
- AMIX N/A
- XRTX N/A
- Revenue This Year
- AMIX N/A
- XRTX N/A
- Revenue Next Year
- AMIX N/A
- XRTX N/A
- P/E Ratio
- AMIX N/A
- XRTX N/A
- Revenue Growth
- AMIX N/A
- XRTX N/A
- 52 Week Low
- AMIX $1.14
- XRTX $0.80
- 52 Week High
- AMIX $42.40
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- AMIX 56.55
- XRTX 51.52
- Support Level
- AMIX $1.35
- XRTX $0.84
- Resistance Level
- AMIX $1.70
- XRTX $0.97
- Average True Range (ATR)
- AMIX 0.13
- XRTX 0.08
- MACD
- AMIX 0.03
- XRTX 0.00
- Stochastic Oscillator
- AMIX 86.87
- XRTX 48.11
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.